!DOCTYPE html> ACTTION

February 5, 2014: Drs. Rice and Dworkin Authors of Article in the Lancet


Dr. Andrew Rice, Europain liaison to ACTTION, and Dr. Robert Dworkin, Director of ACTTION, have authored an article published in the Lancet describing the results of a placebo-controlled, double-blind randomized phase 2 clinical trial in patients with postherpetic neuralgia. The results of the trial showed that patients administered an angiotensin II type 2 receptor antagonist reported significantly less pain than patients who received placebo in the final week of a 28-day treatment period. The article was highlighted by the journal as an "Editor's Choice," and as noted in an accompanying Commentary by Drs. Nanna Finnerup and Cathrine Baastrup, the trial included several novel methodologic features recommended in recent IMMPACT publications on increasing assay sensitivity in analgesic trials.

Rice ASC, Dworkin RH, McCarthy TD, Anand P, Bountra C, McCloud PI, Hill J, Cutter G, Kitson G, Desem N, Raff M. EMA401, an orally administered highly selective angiotensin II type 2 receptor antagonist, as a novel treatment for postherpetic neuralgia: a randomised, double-blind, placebo-controlled phase 2 clinical trial. Lancet, early online publication, 5 February 2014. doi:10.1016/S0140-6736(13)62337-5http://www.thelancet.com/images/clear.gif.